This underscores the importance of PARPis, such as talazoparib and olaparib, both potent inducers of PARP trapping, in the clinical treatment of HR-deficient breast and ovarian cancer caused by BRCA1/2 mutations (BRCAm) (4). The gene discussed is BRCA1; the disease is ovarian carcinoma.